166 related articles for article (PubMed ID: 27707899)
1. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
3. Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300.
Uttarkar S; Dukare S; Bopp B; Goblirsch M; Jose J; Klempnauer KH
Mol Cancer Ther; 2015 Jun; 14(6):1276-85. PubMed ID: 25740244
[TBL] [Abstract][Full Text] [Related]
4. Targeting the transcription factor Myb by small-molecule inhibitors.
Uttarkar S; Frampton J; Klempnauer KH
Exp Hematol; 2017 Mar; 47():31-35. PubMed ID: 28017646
[TBL] [Abstract][Full Text] [Related]
5. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
6. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
[TBL] [Abstract][Full Text] [Related]
7. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
[TBL] [Abstract][Full Text] [Related]
8. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
[TBL] [Abstract][Full Text] [Related]
10. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
Elife; 2021 Feb; 10():. PubMed ID: 33527899
[TBL] [Abstract][Full Text] [Related]
11. The adaptor protein ARA55 and the nuclear kinase HIPK1 assist c-Myb in recruiting p300 to chromatin.
Bengtsen M; Sørensen L; Aabel L; Ledsaak M; Matre V; Gabrielsen OS
Biochim Biophys Acta Gene Regul Mech; 2017 Jul; 1860(7):751-760. PubMed ID: 28495617
[TBL] [Abstract][Full Text] [Related]
12. Design and Biochemical Characterization of Peptidic Inhibitors of the Myb/p300 Interaction.
Jones M; Grosche P; Floersheimer A; André J; Gattlen R; Oser D; Tinchant J; Wille R; Chie-Leon B; Gerspacher M; Ertl P; Ostermann N; Altmann E; Manchado E; Vorherr T; Chène P
Biochemistry; 2023 Apr; 62(7):1321-1329. PubMed ID: 36883372
[TBL] [Abstract][Full Text] [Related]
13. Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
Schmidt TJ; Klempnauer KH
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408476
[TBL] [Abstract][Full Text] [Related]
14. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia.
Zhao H; Jin S; Gewirtz AM
J Biol Chem; 2012 Jan; 287(2):925-34. PubMed ID: 22110127
[TBL] [Abstract][Full Text] [Related]
15. Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.
Biyanee A; Yusenko MV; Klempnauer KH
Cells; 2022 Mar; 11(7):. PubMed ID: 35406726
[TBL] [Abstract][Full Text] [Related]
16. A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.
Yusenko M; Jakobs A; Klempnauer KH
Sci Rep; 2018 Sep; 8(1):13159. PubMed ID: 30177851
[TBL] [Abstract][Full Text] [Related]
17. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb.
Joy ST; Henley MJ; De Salle SN; Beyersdorf MS; Vock IW; Huldin AJL; Mapp AK
J Am Chem Soc; 2021 Sep; 143(37):15056-15062. PubMed ID: 34491719
[TBL] [Abstract][Full Text] [Related]
18. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
19. A conserved patch of hydrophobic amino acids modulates Myb activity by mediating protein-protein interactions.
Dukare S; Klempnauer KH
Biochim Biophys Acta; 2016 Jul; 1859(7):914-21. PubMed ID: 27080133
[TBL] [Abstract][Full Text] [Related]
20. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation.
Sandberg ML; Sutton SE; Pletcher MT; Wiltshire T; Tarantino LM; Hogenesch JB; Cooke MP
Dev Cell; 2005 Feb; 8(2):153-66. PubMed ID: 15691758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
